Skip to Content

Join the 'High Cholesterol - Familial Heterozygous' group to help and get support from people like you.

High Cholesterol - Familial Heterozygous News

Related terms: Familial Hypercholesterolemia, Heterozygous, Heterozygous Familial Hypercholesterolemia, Heterozygous FH, Hypercholesterolemia, Familial Heterozygous

FDA Approves Repatha for High Cholesterol

Posted 5 hours ago by Drugs.com

FRIDAY, Aug. 28, 2015 – Repatha (evolocumab) has been approved by the U.S. Food and Drug Administration, the second non-statin drug in its class approved to treat high cholesterol. The injected drug, among a new class called PCSK9 inhibitors, is sanctioned for people who are unable to reduce levels of the so-called LDL "bad" cholesterol with statin therapy and exercise, the agency said in a news release. Low-density lipoprotein, commonly known as LDL, builds up in the blood from natural and food sources, and is a leading cause of heart disease. About one in four deaths in the United States is linked to heart disease, making it the top cause of death among men and women. The condition kills about 610,000 people in the United States annually, the FDA said. Repatha is an antibody that targets the PCSK9 protein, which inhibits the liver's ability to remove LDL from the blood. Its most ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Repatha, Evolocumab

FDA Approves Repatha - Second Drug in New Class of Cholesterol-Lowering Medications

Posted 5 hours ago by Drugs.com

THURSDAY, Aug. 27, 2015 – The U.S. Food and Drug Administration on Thursday approved a second drug that's part of a potent new class of medications that sharply cut levels of "bad" LDL cholesterol. Repatha (evolocumab), an injectable drug, works by blocking a protein that interferes with the liver's ability to remove LDL cholesterol from the blood. In July, the FDA approved Praluent (alirocumab), another injectable drug in the same class of medications as Repatha. Both drugs are called PCSK9 inhibitors, which don't seem to cause the muscle problems that cholesterol-lowering statin drugs sometimes can. "Repatha provides another treatment option in this new class of drugs for patients with familial hypercholesterolemia or with known cardiovascular disease who have not been able to lower their LDL cholesterol enough with statins," said Dr. John Jenkins, director of the FDA's Office of New ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Repatha, Evolocumab

FDA Approves Repatha (evolocumab) to Treat Certain Patients with High Cholesterol

Posted 6 hours ago by Drugs.com

August 27, 2015 – The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, is approved for use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease, such as heart attacks or strokes, who require additional lowering of LDL cholesterol. Familial hypercholesterolemia (encompassing both HeFH and HoFH) is an inherited condition that causes high levels of LDL cholesterol. A high level of LDL cholesterol in the blood is linked to cardiovascular or heart disease. Heart ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Repatha, Evolocumab

FDA OKs Praluent - First of New Class of Cholesterol Drugs

Posted 27 Jul 2015 by Drugs.com

FRIDAY, July 24, 2015 – The U.S. Food and Drug Administration on Friday approved Praluent, the first of a powerful new class of injected, cholesterol-lowering drugs that experts believe could change cardiovascular care. Praluent (alirocumab) sharply cuts levels of LDL ("bad") cholesterol, and is one of a group of newly developed drugs called PCSK9 inhibitors, the FDA explained in a news release. The drug is only approved for patients with heart disease and a history of heart attack or stroke "who require additional lowering of LDL cholesterol" in addition to taking a statin drug and adopting a healthy diet, the agency said. It is also for use by patients with a condition called heterozygous familial hypercholesterolemia (HeFH), an inherited illness that causes people to have high levels of LDL in the blood. "Praluent provides another treatment option for patients with HeFH or with ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Praluent, Alirocumab

Praluent Approved to Treat High Cholesterol

Posted 27 Jul 2015 by Drugs.com

MONDAY, July 27, 2015 – Praluent (alirocumab) injection has been approved by the U.S. Food and Drug Administration to treat people with inherited high cholesterol (heterozygous familial hypercholesterolemia) or people at risk of heart attack or stroke from high cholesterol derived from foods or produced by the liver. The drug is sanctioned for people who do not benefit enough from improved diet and the use of cholesterol-lowering statins. Low-density lipoprotein (LDL, the so-called "bad cholesterol") is linked to cardiovascular disease. Heart disease is the leading cause of death among American men and women, killing some 610,000 people every year, the FDA said in a news release. Praluent is the first-approved drug in a new class of medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. The drug is an antibody that inhibits the PCSK9 protein, which allows ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Praluent, Alirocumab

FDA Approves Praluent (alirocumab) to Treat Certain Patients with High Cholesterol

Posted 27 Jul 2015 by Drugs.com

July 24, 2015 – The U.S. Food and Drug Administration today approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol. HeFH is an inherited condition that causes high levels of low-density lipoprotein (LDL) cholesterol. A high level of LDL cholesterol (known as “bad” cholesterol) in the blood is linked to cardiovascular disease. Heart disease is the number one cause of death for Americans, both men and women. According to the Centers for Disease Con ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, Praluent, Alirocumab

Wider Use of Statin Drugs Could Save Thousands More Lives: Report

Posted 14 Jul 2015 by Drugs.com

TUESDAY, July 14, 2015 – New expert guidelines from two major cardiologists' groups may boost doctors' ability to spot patients who should take cholesterol-lowering statin drugs, researchers said. The updated guidelines were released in 2013 by the American College of Cardiology and the American Heart Association. Now, a new report finds they are more accurate and efficient than earlier guidelines in identifying adults at high risk for heart trouble who could gain from statins. All of that should add up to lives saved, the researchers said. "Extrapolating our results to the approximately 10 million U.S. adults who would be newly eligible for statin therapy under the new guidelines, we estimate that between 41,000 and 63,000 cardiovascular events – heart attacks, strokes or deaths from cardiovascular disease – would be prevented over a 10-year period," lead researcher Dr. Udo Hoffman, ... Read more

Related support groups: Heart Disease, High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Rosuvastatin, Hypertriglyceridemia, Coronary Artery Disease (CAD), High Cholesterol - Familial Heterozygous, Red Yeast Rice, Livalo, Pravachol, High Cholesterol - Familial Homozygous, Cardiovascular Risk Reduction, Hyperlipoproteinemia, Lescol

Do Cholesterol Drugs Affect Aggression?

Posted 1 Jul 2015 by Drugs.com

WEDNESDAY, July 1, 2015 – Cholesterol-lowering statin drugs might influence a person's aggressive behaviors, increasing or decreasing their irritability and violent tendencies, a new clinical trial suggests. Men taking statins typically become less aggressive, while women on statins tend to become more aggressive, according to findings published July 1 in the journal PLOS ONE. "Clinicians should be aware of this, and it's not bad for patients to be aware of it," said lead author Dr. Beatrice Golomb, a principal investigator at the University of California, San Diego School of Medicine. "If an individual develops a behavioral change, in my view medication should always be considered as a possibility." However, the effect appears to be minimal and needs to be verified with follow-up studies, said one outside expert, Robert Geffner, founding president of the Institute on Violence, Abuse & ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Red Yeast Rice, Livalo, Pravachol, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol, Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Lescol XL

Half of U.S. Hispanics With High Cholesterol Unaware They Have It: Study

Posted 24 Jun 2015 by Drugs.com

WEDNESDAY, June 24, 2015 – Nearly half of Hispanic people in the United States with high cholesterol levels aren't aware they have the health problem and more than two-thirds who are aware aren't being treated, a new study indicates. Reviewing data from more than 16,000 Hispanics between the ages of 18 and 74, the researchers found that about 44 percent of men and 40 percent of women had high cholesterol, greater proportions overall than among the general U.S. population. Almost one-third of all American adults have high levels of low-density lipoprotein (LDL) or "bad" cholesterol, according to the U.S. Centers for Disease Control and Prevention, and less than a third have the condition under control. High cholesterol levels are a major risk factor for developing heart disease or stroke since a build-up of the fatty substance can narrow blood vessels and hinder blood flow to the heart ... Read more

Related support groups: High Cholesterol, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL), Hyperlipoproteinemia Type III (Elevated beta-VLDL + IDL), Hyperlipoproteinemia Type IV (Elevated VLDL)

Health Tip: What's Behind High Cholesterol?

Posted 24 Jun 2015 by Drugs.com

-- High cholesterol is a risk factor for serious health problems, from heart attack to stroke. The National Heart Lung and Blood Institute mentions these possible causes: Eating a diet high in cholesterol-rich foods, such as meat, cheese, egg yolks and other animal products. Foods high in saturated and trans fats also increase cholesterol. Being overweight or lack of physical activity can lead to extra pounds and boost cholesterol. Being age 55 or older increases your risk of high cholesterol. Having an inherited condition called familial cholesterolemia leads to high cholesterol. Read more

Related support groups: Obesity, High Cholesterol, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL), Hyperlipoproteinemia Type III (Elevated beta-VLDL + IDL), Hyperlipoproteinemia Type IV (Elevated VLDL), Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL)

Can U.S. Health-Care System Afford New, Improved Cholesterol Drugs?

Posted 18 Jun 2015 by Drugs.com

THURSDAY, June 18, 2015 – A new class of powerful cholesterol drugs is poised to hit the market, and doctors are both hopeful about their potential, and worried that insurers won't pay for them. The drugs, known as PCSK9 inhibitors, can drastically cut LDL cholesterol – the "bad" kind linked to increased risks of heart attack and stroke. And they are expected to open up a new option for people who cannot take statins, the drugs that have been the standard for cholesterol-lowering since the 1980s. Last week, an advisory panel to the U.S. Food and Drug Administration recommended the agency approve two PCSK9 inhibitors: alirocumab (Praluent) and evolocumab (Repatha). The FDA, which usually follows the recommendations of its advisory panels, is expected to OK both drugs. Some cardiologists have heralded PCSK9 inhibitors as a breakthrough – particularly for patients who can't take statins ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Zetia, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Red Yeast Rice, Livalo, Pravachol, High Cholesterol - Familial Homozygous, Ezetimibe, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol

FDA Advisers Recommend Approval of 2nd New Cholesterol Drug

Posted 10 Jun 2015 by Drugs.com

WEDNESDAY, June 10, 2015 – U.S. health officials recommended Wednesday the approval of a second new drug that's part of a novel class of medications that sharply cut "bad" LDL cholesterol. In an 11-4 vote, a U.S. Food and Drug Administration advisory panel endorsed the drug evolocumab (Repatha) for use in patients who are at very high risk for high cholesterol. On Tuesday, the same panel of experts recommended approval of a similar drug known as alirocumab (Praluent). Both medications belong to a new class of drugs called PCSK9 inhibitors. But the advisory panel reiterated concerns that the real benefits of these drugs need to be determined in long-term studies. While the FDA isn't compelled to follow the recommendations of its advisory committees, it usually does so. How these drugs will be prescribed will depend largely on what prescribing information the FDA writes for these ... Read more

Related support groups: High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous

Cholesterol Drugs May Lower Stroke Risk for Healthy Older Adults

Posted 19 May 2015 by Drugs.com

TUESDAY, May 19, 2015 – Healthy older adults who take cholesterol-lowering drugs may be cutting their risk of stroke, a new French study suggests. The study found that when people took medications called statins or fibrates, their risk of stroke over almost a decade went down by about one-third. But, lead researcher Dr. Christophe Tzourio, a professor of epidemiology at the University of Bordeaux and Inserm in France, doesn't think older people should start taking these drugs solely for stroke prevention. "Our results should not be interpreted as an indication for prescribing statins or fibrates to elderly individuals. We wouldn't recommend changing medications based on the results of only one study," he said. "The next step is to see whether we can replicate our findings or not," he added. The report was published May 19 in the BMJ. Statins include drugs such as Lipitor and Zocor. ... Read more

Related support groups: Ischemic Stroke, High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Transient Ischemic Attack, Tricor, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Red Yeast Rice, Livalo, Ischemic Stroke - Prophylaxis, Pravachol, High Cholesterol - Familial Homozygous, Thromboembolic Stroke Prophylaxis

Staying Fit May Delay Onset of High Cholesterol, Study Finds

Posted 11 May 2015 by Drugs.com

MONDAY, May 11, 2015 – Men who keep fit may find they delay normal age-related increases in blood cholesterol levels by up to 15 years, a new study suggests. It is common for cholesterol levels to rise with age and then decrease later in life, the study authors explained in background notes. Previous studies have shown that high cholesterol levels can be a risk factor for heart disease. Regular physical activity can lower this risk, the researchers said. "Exercise and being fit helps keep arteries clear by lowering 'bad' [LDL] cholesterol and boosting 'good' [HDL] cholesterol," explained study author Dr. Xuemei Sui, an assistant professor at the Arnold School of Public Health at the University of South Carolina in Columbia, S.C. "It also reduces other risk factors for atherosclerosis [narrowed arteries] and blood clots, such as high blood pressure, diabetes, obesity and stress," Sui ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Zetia, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Red Yeast Rice, Livalo, Pravachol, High Cholesterol - Familial Homozygous, Ezetimibe, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol

Americans' Blood Triglyceride Levels Dropping: CDC

Posted 7 May 2015 by Drugs.com

THURSDAY, May 7, 2015 – Americans' levels of triglycerides – a type of fat in the blood – have dropped significantly in the past decade, according to a new federal study. Factors that may lower triglyceride levels include quitting smoking, weight loss, use of cholesterol-lowering drugs (such as statins) and improving dietary nutrition, the researchers said. "The news is encouraging," said Dr. Michael Miller, a professor at the University of Maryland School of Medicine in Baltimore. But Miller, who was not involved with the study, added that it is "certainly nothing to brag about when one out of every three middle-aged men 40 to 59, and nearly one out of every three women aged 60 and over continue to live with unhealthy triglyceride levels." Like the bad type of cholesterol – LDL – high levels of triglycerides raise the risk of clogged arteries and heart disease. Another expert, Dr. ... Read more

Related support groups: High Cholesterol, Lipitor, Simvastatin, Crestor, Pravastatin, Atorvastatin, Zocor, Lovastatin, Rosuvastatin, Hypertriglyceridemia, High Cholesterol - Familial Heterozygous, Red Yeast Rice, Livalo, Pravachol, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia Type IIa (Elevated LDL), Hyperlipoproteinemia, Lescol, Lescol XL, Mevacor

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

High Cholesterol

Related Drug Support Groups

Lipitor, simvastatin, Crestor, pravastatin, atorvastatin, Zocor, lovastatin, Zetia, Vytorin, view more... rosuvastatin, Pravachol, ezetimibe, Lescol, Lescol XL, Advicor, Mevacor, fluvastatin, Praluent, Altoprev, Altocor, Juvisync, Repatha, ezetimibe / simvastatin, lovastatin / niacin, alirocumab, evolocumab, simvastatin / sitagliptin